Kallyope, Inc. is a clinical stage biotechnology company focused on discovering and developing novel, oral small-molecule therapeutics for diseases with high unmet need, including obesity, Type 2 diabetes, neurological disorders, and gastrointestinal diseases.

Kallyope, Inc.

At Kallyope, we focus on big health challenges that matter to patients and families. We aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. 

Inside every human body is a complex, unexplored network of metabolic, neurological, and gastrointestinal interconnections. Our scientists are unlocking the mysteries of this network to develop oral therapies for obesity and diabetes; neurological disorders, including migraine; and gastrointestinal disease, including celiac disease.

Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development.

Together, we are leveraging multiple sophisticated technologies and internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health.

Bill & Melinda Gates Foundation

Polaris Partners

Lux Capital

Alexandria Venture Investments

Euclidean Capital

Greenspring Associates

Illumina Ventures

Casdin Capital

The Column Group

Two Sigma Ventures

Bill Gates

DNS Capital

Hartford HealthCare Endowment

StepStone Group

Tao Capital Partners

Kallyope

𝗗𝗮𝗻𝗶𝗲𝗹 𝗗𝗿𝘂𝗰𝗸𝗲𝗿, 𝗝𝗲𝗳𝗳 𝗚𝗼𝗿𝗱𝗼𝗻, 𝗥𝘂𝘀𝗹𝗮𝗻 𝗠𝗲𝗱𝘇𝗵𝗶𝘁𝗼𝘃 𝗮𝗻𝗱 𝗪𝗲𝗻𝗱𝘆 𝗬𝗼𝘂𝗻𝗴 𝗮𝗽𝗽𝗼𝗶𝗻𝘁𝗲𝗱 𝘁𝗼 𝗞𝗮𝗹𝗹𝘆𝗼𝗽𝗲 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗔𝗱𝘃𝗶𝘀𝗼𝗿𝘆 𝗕𝗼𝗮𝗿𝗱

The Kallyope team is proud to announce the appointment of four distinguished physicians and scientists to our #ScientificAdvisoryBoard: Daniel Drucker, M.D., a prominent endocrinologist who has made seminal contributions to the discovery and development of GLP-1 and GLP-2 based therapeutics; Jeff Gordon, M.D., a leader in the fields of microbiome biology and gastroenterology; Ruslan Medzhitov, Ph.D., an outstanding scientist focusing on inflammation and allergy who studies the biology of inflammation, allergy, and mechanisms of homoeostasis and diseases; and Wendy Young, Ph.D., who brings more than 25 years of experience in the development of innovative medicines. We at Kallyope are honored to welcome these life sciences leaders and are confident that their independent strategic advice and perspectives will support and enable our continued scientific and clinical advancement. #DrugDiscovery #Biotechnology

Very pleased that Kallyope is the focus of a feature article by Biocentury Director of Biopharma Intelligence Stephen Hansen, “Translating bariatric surgery weight loss into a pill,” highlighting how our oral approach to treating #obesity differs from GLP-1 agonists. The piece provides  insight into how we’ve developed the unique nutrient receptor agonists K-757 and K-833, currently in Phase 2 clinical trials, that aim to prolong  plasma levels of GLP-1 and other gut hormones, with the potential effect of reducing appetite and improving glucose control. Read more: https://lnkd.in/gKCEhyUQ #type2diabetes #obesitytreatment #obesityprevention

We’re pleased to share Jay Galeota's piece in BioSpace, “Addressing the Obesity Epidemic: The Need for New Oral Agents,” that outlines the urgency of developing new therapeutic classes to benefit the many underserved patients living with #obesity. Of 100 million adults with obesity in the U.S., only a small percent are treated, and multiple approaches, including oral treatments, will be critical to address unmet patient need. Read more: https://lnkd.in/ekX8TDku #obesitytreatment #obesityprevention

The Kallyope team marked the completion of our second year collaborating with Columbia University students enrolled in the Columbia Business School Healthcare Management, Design, and Strategy course. This year’s fantastic group — students Christine H., Shailen Sampath, Alejandro Sousa, Phillip Chung, and Sujaan Sanghvi, together with Kallyope's Maury Spadoto and Robert Barretto — had the opportunity to navigate strategic decision-making challenges in the healthcare industry by providing a strategic analysis of raising capital in today's biotech market — and they crushed it! At Kallyope, we’re proud to be Made in New York and thrilled to partner with one of our city’s most prestigious universities to help inspire future healthcare leaders. #columbiabusinessschool #entrepreneurship

Congratulations to Nancy Thornberry, founding CEO, chair of R&D, and board member of Kallyope, on being named to the board of directors of Vertex Pharmaceuticals, the Boston-based global biotechnology company dedicated to creating transformative medicines for people with serious and life-threatening diseases. All of us at Kallyope have long been benefiting from Nancy’s pioneering spirit, scientific and corporate leadership, and commitment to collaboration, and we are excited for her opportunity to work with Vertex to improve the lives of patients everywhere. Read more: https://lnkd.in/gJzPacaS

Together with Sosei Heptares, we are pleased to announce the first scientific milestone stemming from the strategic drug discovery collaboration between the two companies announced in 2022: the successful identification, validation, and nomination of a first G-protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for gastrointestinal disease.
 
As Jay Galeota, president and CEO, Kallyope, notes, “This achievement further confirms the effectiveness of Kallyope’s unique target discovery platform and scientific expertise, and the value of collaboration with the GPCR platform and expertise of Sosei Heptares.” Read more https://lnkd.in/e_vqpuAq  #DrugDiscovery #DrugDevelopment

Great panel discussion yesterday on #obesity treatments in development and the myriad issues around weight loss at The Next Frontier of the #LifeSciences virtual event, hosted by PharmaVoice and BioPharma Dive and featuring Kallyope Chief Medical Officer Brett Lauring, and fellow CMOs David Kendall, of Zealand Pharma and Ashish Nimgaonkar, of Glyscend Therapeutics. As Brett noted, it’s important to view obesity as a chronic disease that cannot be treated by one-size-fits-all interventions, and the role of companies like Kallyope is to introduce easy-to-use, affordable, and scalable therapies. #pharma #biotech #Type2Diabetes

Join Kallyope Chief Medical Officer Brett Lauring, M.D., Ph.D. today at 2:55 ET at The Next Frontier of the #LifeSciences virtual event, hosted by PharmaVoice and BioPharma Dive. Brett’s panel will discuss how recent breakthroughs could begin to improve the way we manage #obesity, a disease that affects more than 100 million Americans. https://lnkd.in/gVAC3msr #Type2Diabetes #pharma #biotech

The Kallyope team looks forward to ObesityWeek® #OW2023 next week in #Dallas, the preeminent event to discuss developments related to #obesity clinical research, treatment and prevention and the latest efforts in advocacy and public policy. Kallyope has just entered Phase 2 with K-757 and K-833, our first-in-class oral approach for the treatment of both obesity and #Type2diabetes. #obesitytreatment #obesityprevention

Team Kallyope hit the streets yesterday as part of Miles for Migraine, an annual NYC 5K run/walk to raise awareness and funds for those affected by this “invisible disease” affecting 1 in 4 households in the U.S. Kallyope is leveraging a unique combination of leading technologies and internally-developed capabilities to develop fundamentally new solutions for migraine. #HeadacheAwareness #MigraineAwareness #migraine

COM:KALLYOPE

Kallyope, Inc.